Latest News
11.06.2023
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
10.30.2023
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
09.25.2023
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases.
Advancing transformative medicines for neurological diseases.
Our pipeline includes genetic medicines for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system.
Revolutionizing delivery across the blood-brain barrier.
Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which has generated novel capsids that demonstrate exceptional delivery across the blood-brain barrier following intravenous dosing in preclinical studies.
Our people are our most valuable resource.
We are looking for dedicated professionals who share our passion for advancing transformative neurogenetic medicines.
“My career trajectory at Voyager has been really great. I’ve found a lot of opportunities to grow.”